$AGX

Argan (AGX) reported record Q2 revenue of $384.0M (+61.5% YoY) and net income of $53.3M, driven by its Power segment. Gross margin slipped to 19.3%, and backlog decreased to $2.5B. The company is debt-free with $1.03B in cash, returning $51.7M to shareholders. Management expects new projects but faces regulatory challenges and margin compression.

Zacks upgraded five stocks to Strong Buy: RCM Technologies (RCMT), Healthcare Services Group (HCSG), Bloomin' Brands (BLMN), Argan (AGX), and Globus Medical (GMED). Their earnings estimates rose 13.3%, 12.9%, 10.1%, 6.7%, and 5.3% respectively in 60 days.

Argan (AGX) stock fell 8% after Piper Sandler analyst Dimple Gosai initiated coverage with an underweight rating and a $273 price target, citing capacity limits and a potential peak in project awards.

Argan (AGX) reported Q2 2027 revenue of $384.0M, up 61.5%, with net income of $53.3M ($3.76 per diluted share). Power segment revenue grew 53% YoY to $301M, while Industrial segment revenue rose 111% to $76M. Consolidated backlog decreased to $2.5B. The company plans to complete a new fabrication facility in North Carolina by Q3 2027.

Argan, Inc. (AGX) reported 56.5% revenue growth to $674.9M and adjusted EBITDA growth to $126.5M in H1 2027. The company expects 45.4% sales and 38% earnings growth for fiscal 2027, with a $2.5B backlog. However, margins have declined, and valuation remains high. Management highlights multi-year visibility but warns of execution risks.

Argan, Inc. (AGX) shares fell 28.1% in a month, despite strong Q2 FY2027 results with 61.5% revenue growth to $384M and 50.4% EPS growth to $3.76. Backlog declined to $2.5B, and margins fell to 19.3%. Management cited project timing and mix as factors. AGX trades at 33.1X earnings, above industry peers.

Argan, Inc. (AGX) reported record Q2 2027 revenue of $384M, net income of $53M, and adjusted EBITDA of $70M. Freedom Broker upgraded AGX to Buy with a $700 price target, citing strong project execution and a $2.5B backlog. However, Industrial segment margins fell to 7.3%, and hedge fund interest slightly decreased.

Benzinga identifies Argan (NYSE:AGX), RBC Bearings (NYSE:RBC), and Park Aerospace (NYSE:PKE) as oversold industrials stocks with RSI values near or below 30. RBC Bearings acquired PSC Couplings for $24.2M, Park Aerospace appointed a new CFO, and Argan reported better-than-expected Q2 results. All three stocks have declined significantly over the past month.

Argan (AGX) stock surged 9.4% in pre-market trading after reporting record Q2 results. Adjusted EPS of $3.76 beat estimates of $2.66, while revenue of $384 million exceeded forecasts of $299 million. The power segment drove growth, with $301 million in revenue and a 53% YoY increase. The company has a $2.8 billion project backlog, signaling strong future demand. The broader market was flat, indicating the rally was company-specific.

Argan Inc. reported Q2 2026 revenue of $383.98M, up 61.5% YoY, and EPS of $3.76, up 50.4%. Net income rose 51.1% to $53.3M. Growth was driven by the Power segment, which contributed 78% of revenue. The company's backlog stands at $2.5B, with several large projects underway.